The primary purpose of this study is to help answer if LY2127399 is safe and effective in the
treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic
drug (DMARD) therapy.
This study is comprised of 2 periods:
Period 1 - 24-week blinded treatment
Period 2 - 48-week post-treatment follow-up